Methods for manufacturing porous polymeric articles
By combining polymers with sugars or salts to form porous polymeric articles, the method achieves tunable pore sizes for controlled release, addressing the lack of control in existing technologies and ensuring low cytotoxicity for medical applications.
Patent Information
- Application Number
- PCT/US2026/027146
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for introducing porosity into polymeric articles lack tunable control over pore size, which is crucial for controlling the release of cargo within these articles.
A method involving the combination of polymers with sugars or salts to create polymer mixtures, followed by fabrication and water contact to form porous polymeric articles with tunable pore sizes ranging from 125 to 1200 nanometers, achieved through processes like electrospinning, solution casting, or additive manufacturing.
Enables precise control over pore size, allowing for controlled release of therapeutic agents and demonstrating low cytotoxicity to cells, suitable for medical implants such as ocular implants.
Smart Images

Figure US2026027146_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No. IO3362-137WO1
[0002] METHODS FOR MANUFACTURING POROUS POLYMERIC ARTICLES
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS
[0004] This application claims the benefit of priority to United States Provisional Patent Application No. 63 / 801,316, filed May 7, 2025, the disclosure of which is incorporated herein by reference in its entirety.
[0005] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0006] This invention was made with government support under R01 EB032870 awarded by the National Institutes of Health. The Government has certain rights in the invention.
[0007] BACKGROUND
[0008] Introducing pores into polymeric articles is often desired in order to facilitate the controlled release of a cargo within the polymeric article. The rate of release is often determined by pore size. Standard methods for introducing porosity into polymeric articles provide difficult control of the pore size of the resulting article. There is a clear need for methods that can allow tunable control of pore size when manufacturing such articles.
[0009] SUMMARY
[0010] The present disclosure is directed to methods of manufacturing porous polymeric articles with tunable selectivity of pore size. Manufacturing of polymeric articles with particular pore sizes can be performed by selecting the appropriate porogen as detailed in this disclosure.
[0011] In some aspects, a method is provided of manufacturing a porous polymeric article having an average pore diameter from 125 to 375 nanometers. In some aspects, the method can include combining at least one polymer and at least one sugar to create a polymer mixture. In some aspects, the method can further include fabricating an article from the polymer mixture. In some aspects, the method can further includeAttorney Docket No. IO3362-137WO1
[0012] drying the article. In some aspects, the method can further include contacting the article with water to form the porous polymeric article.
[0013] In another aspect, a method is provided of manufacturing a porous polymeric article having an average pore diameter from 400 to 1200 nanometers. In some aspects, the method can include combining at least one polymer and at least one salt to create a polymer mixture. In some aspects, the method can include fabricating the polymer mixture into an article. In some aspects, the method can include drying the article. In some aspects, the method can include contacting the article with water to form the porous polymeric article.
[0014] The details of one or more aspects of the disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the disclosure will be apparent from the description, the drawings, and the claims.
[0015] DESCRIPTION OF DRAWINGS
[0016] FIG. 1 is a photograph of the electrospinning setup as used in the preparation of nanofibrous mats as described in the examples.
[0017] FIGs. 2A and 2B provide representative SEM images of (FIG. 2A) PCL / HEPES sodium salt and (FIG. 2B) PCL / sucrose nanofibers after electrospinning as described in the examples.
[0018] FIG. 3 provides SEM images depicting the nanoporosity of PCL nanofibers with different HEPES sodium salt concentrations as described in the examples.
[0019] FIG. 4 provides data regarding the cytotoxicity to ARPE-19 cells when exposed to PCL / HEPES sodium salt and PCL / sucrose by the direct contact method and extract exposure method as described in the examples.
[0020] FIGs. 5A and 5B provide SEM images of PCL nanofibers formed from acetic acid solution (FIG. 5A) and an equivalent gold-plated SEM image (FIG. 5B).
[0021] FIG. 6 provides a gold-plated SEM image of PCL / HEPES sodium salt nanofibers formed from acetic acid / solution.
[0022] FIGs. 7A and 7B provide SEM images of PCL / sucrose nanofibers formed from acetic acid solution (FIG. 7A) and an equivalent gold-plated SEM image (FIG. 7B).Attorney Docket No. IO3362-137WO1
[0023] FIG. 8 provides a schematic of the tunable porogen-loaded PCL preparation process as described in the examples.
[0024] FIGs. 9A and 9B provide SEM images of nanopores before (FIG. 9A) and after (FIG.
[0025] 9B) porogen leaching in the PCL implant produced from 5% HEPES sodium salt concentration as described in the examples.
[0026] FIGs. 10A and 10B provide SEM images of nanopores before (FIG. 10A) and after (FIG. 10B) porogen leaching in the PCL implant produced with 5% sucrose concentration as described in the examples.
[0027] FIGs. 11A and 11B provide data regarding the tensile strength of the PCL implant at different porogen contents as described in the examples.
[0028] FIGs. 12A and 12B provide data regarding the in vitro cytotoxicity to ARPE-19 cells with implants described in the examples by (FIG. 12A) direct contact method and (FIG. 12B) extract exposure method.
[0029] DETAILED DESCRIPTION
[0030] The following description of the disclosure is provided as an enabling teaching of the disclosure in its best, currently known aspects. Many modifications and other aspects disclosed herein will come to mind to one skilled in the art to which the disclosed compositions and methods pertain, benefiting from the teachings presented in the descriptions herein and the associated drawings. Therefore, it is understood that the disclosures are not limited to the specific aspects disclosed and that modifications and other aspects are intended to be included within the scope of the appended claims. The skilled artisan will recognize many variants and adaptations of the aspects described herein. These variants and adaptations are intended to be included in the teachings of this disclosure and to be encompassed by the claims herein. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
[0031] As is apparent to those of skill in the art upon reading this disclosure, each of the individual aspects described and illustrated herein has discrete components and features that may be readily separated from or combined with the features of any of the other several aspects without departing from the scope or spirit of the present disclosure.Attorney Docket No. IO3362-137WO1
[0032] Any recited method can be carried out in the order of events recited or any other order that is logically possible. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not explicitly state in the claims or descriptions that the steps are to be limited to a particular order, it is in no way intended that an order be inferred in any respect. This holds for any possible non-express basis for interpretation, including logic concerning the arrangement of steps or operational flow, meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
[0033] All publications mentioned herein are incorporated by reference to disclose and describe the methods or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure before the filing date of the present application. Further, the publication dates provided herein may differ from the actual publication dates, which may require independent confirmation.
[0034] It is also to be understood that the terminology herein describes particular aspects only and is not intended to be limiting. Unless defined otherwise, all technical and scientific terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosed compositions and methods belong. It can be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the specification and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly defined herein. Before describing the various aspects of the present disclosure, the following definitions are provided and should be used unless otherwise indicated. Additional terms may be defined elsewhere in the present disclosure.
[0035] Definitions
[0036] As used herein, “comprising” is interpreted as specifying the presence of the stated features, integers, steps, or components, but does not preclude the presence or addition of one or more features, integers, steps, components, or groups thereof. Moreover, each of the terms “by,” “comprising,” “comprises,” “comprised of,”Attorney Docket No. IO3362-137WO1
[0037] “including,” “includes,” “included,” “involving,” “involves,” “involved,” and “such as” is used in its open, non-limiting sense and maybe used interchangeably. Further, the term “comprising” is intended to include examples and aspects encompassed by the terms “consisting essentially of” and “consisting of.” Similarly, “consisting essentially of’ is intended to include examples encompassed by the term “consisting of.” As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context dictates otherwise.
[0038] Ratios, concentrations, amounts, and other numerical data can be expressed herein in a range format. Further, the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. There are many values disclosed herein, and each value is also disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Ranges can be expressed herein as from “about” one particular value and to “about” another particular value. Similarly, when values are expressed as approximations, using the antecedent “about,” the particular value forms a further aspect. For example, if the value “about 10” is disclosed, then “10” is also disclosed.
[0039] When a range is expressed, a further aspect includes from the one particular value and to the other particular value. For example, where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure, e.g., the phrase “x to y” includes the range from ‘x’ to ‘y’ as well as the range greater than ‘x’ and less than ‘y’. The range can also be expressed as an upper limit, e.g. ‘about x, y, z, or less’ and should be interpreted to include the specific ranges of ‘about x,’ ‘about y,’ and ‘about z’ as well as the ranges of ‘less than x,’ ‘less than y.’ and ‘less than z.’ Likewise, the phrase ‘about x, y, z, or greater’ should be interpreted to include the specific ranges of ‘about x,’ ‘about y,’ and ‘about z’ as well as the ranges of ‘greater than x,’ greater than y,’ and ‘greater than z.’ In addition, the phrase “about ‘x’ to ‘y’,” where ‘x’ and ‘y’ are numerical values, includes “about ‘x’ to about ‘y’.”
[0040] Such a range format is used for convenience and brevity and should thus be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also all individual numerical values or sub-ranges encompassed within that range, as if each numerical value and sub-range wereAttorney Docket No. IO3362-137WO1
[0041] explicitly recited. To illustrate, a numerical range of “about 0.1% to 5%” should be interpreted to include not only the explicitly recited values of about 0.1% to about 5%, but also include individual values (e.g., about 1%, about 2%, about 3%, and about 4%) and the sub-ranges (e.g., about 0.5% to about 1.1%; about 5% to about 2.4%; about 0.5% to about 3.2%, and about 0.5% to about 4.4%, and other possible subranges) within the indicated range.
[0042] As used herein, the terms “about,” “approximate,” “at or about,” and “substantially” mean that the amount or value in question can be the exact value or a value that provides equivalent results or effects as recited in the claims or taught herein. That is, amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact but may be approximate, larger or smaller, as desired, reflecting tolerances, conversion factors, rounding, measurement error, and the like, and other factors known to those of skill in the art such that equivalent results or effects are obtained. In some circumstances, the value that provides equivalent results or effects cannot be reasonably determined. In such cases, as used herein, “about” and “at or about” mean the nominal value indicated ±10% variation unless otherwise indicated or inferred. In general, an amount, size, formulation, parameter, or other quantity or characteristic is “about,” “approximate,” or “at or about,” whether or not expressly stated to be such. Where “about,” “approximate,” or “at or about” is used before a quantitative value, the parameter also includes the specific quantitative value itself unless expressly stated otherwise.
[0043] As used herein, “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur. The description includes instances in which said event or circumstance occurs and those in which it does not.
[0044] Although the operations of exemplary aspects of the disclosed method may be described in a particular sequential order for convenient presentation, it should be understood that disclosed aspects can encompass an order of operations other than the particular sequential order disclosed. For example, operations described sequentially may, in some cases, be rearranged or performed concurrently. Further, descriptions and disclosures provided in association with one particular aspect are not limited to that aspect and may be applied to any aspect disclosed.Attorney Docket No. IO3362-137WO1
[0045] Compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this disclosure belongs.
[0046] Certain materials, compounds, compositions, and components disclosed herein can be obtained commercially or readily synthesized using techniques generally known to those of skill in the art. For example, the starting materials and reagents used in preparing the disclosed compounds and compositions are either available from commercial suppliers, such as Sigma-Aldrich (formerly MilliporeSigma, Burlington, MA) or Thermo Fisher Scientific Inc. (Waltham, MA), or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis (John Wiley and Sons, 2007); Organic Reactions (John Wiley and Sons, 2004); March's Advanced Organic Chemistry, (John Wiley and Sons, 8thEdition); and Larock's Comprehensive Organic Transformations (John Wiley and Sons, 3rdedition, 2017).
[0047] As used herein, a “polymer” refers to a substance comprising molecules each containing a plurality of repeating covalently bound structural units derived from one or more types of monomer. The term “polymer” includes homopolymers and copolymers unless expressly stated otherwise.
[0048] As used herein, the term ‘monomer’ refers to a molecule that can undergo polymerization, thereby contributing repeating units to the essential structure of a polymer.
[0049] As used herein, “polymerization” refers to a chemical process in which monomer molecules react together to form polymer chains or three-dimensional networks through covalent bonding.
[0050] The present disclosure is directed to methods of manufacturing porous polymeric articles with tunable selectivity of pore size. Manufacturing of polymeric articles with particular pore sizes can be performed by selecting the appropriate porogen as detailed in this disclosure.
[0051] In one aspect, a method of manufacturing a porous polymeric article is provided. In some aspects, the porous polymeric material has an average pore diameter from 125 to 375 nanometers, including exemplary values of 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, or any subrange of the above exemplary values.Attorney Docket No. IO3362-137WO1
[0052] In some aspects, the method can include combining at least one polymer and at least one sugar to create a polymer mixture. In some aspects, the at least one sugar can include sucrose, glucose, fructose, lactose, trehalose, maltose, xylose, allulose, or combinations thereof. In some aspects, the at least one sugar can include sucrose. In some aspects, the at least one sugar can include fructose. In some aspects, the at least one sugar can include lactose. In some aspects, the at least one sugar can include trehalose. In some aspects, the at least one sugar can include maltose. In some aspects, the at least one sugar can include xylose. In some aspects, the at least one sugar can include allulose. In some aspects, the at least one sugar can include a combination of two or more of the above sugars. Other suitable sugars can be readily identified.
[0053] In some aspects, the at least one sugar is present in the polymer mixture at a concentration from 0.1% to 10% by weight, including exemplary values of 0.1%, 0.5%, 1%, 2%, 3%, 4%, 6%, 7%, 8%, 9%, 10%, or any subrange formed from the above exemplary values.
[0054] In another aspect, the porous polymeric article can have an average pore diameter from 400 to 1200 nanometers, including exemplary values of 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, or any subrange formed from the above exemplary values.
[0055] In some aspects, the method can include combining at least one polymer and at least one salt to create a polymer mixture. In some aspects, the at least one salt can include a sulfonate salt. In some aspects, the at least one salt can include 4-(2-hydroxyethyl)-l-piperazineethanesulfonate (HEPES) salt, 3-(IV-morpholino)propanesulfonate (MOPS) salt, piperazine-N,N'-bis(2-ethanesulfonate) (PIPES) salt, 2-{[i,3-Dihydroxy-2-(hydroxymethyl)propan-2-yl]amino}ethane-i-sulfonate (TES) salt, 3-[4-(2-Hydroxyethyl)piperazin-i-yl]propane-i-sulfonate (EPPS) salt, 3-[4-(2-Hydroxyethyl)piperazin-i-yl]propane-i-sulfonate (TAPS) salt, or combinations thereof. In some aspects, the at least one salt can include HEPES salt. In some aspects, the at least one salt can include MOPS salt. In some aspects, the at least one salt can include PIPES salt. In some aspects, the at least one salt can include TES salt. In some aspects, the at least one salt can include EPPS salt. In some aspects, the at least one salt can include TAPS salt. In some aspects, the at least one salt can includeAttorney Docket No. IO3362-137WO1
[0056] a combination of two or more of the above salts. Other suitable salts can be readily identified.
[0057] In some aspects, the at least one salt can include a sodium salt, a potassium salt, or combinations thereof. In some aspects, the at least one salt can include a sodium salt of HEPES, MOPS, PIPES, TES, EPPS, or TAPS. In some aspects, the at least one salt can include a potassium salt of HEPES, MOPS, PIPES, TES, EPPS, or TAPS.
[0058] In some aspects, the at least one salt can be present in the polymer mixture at a concentration from 0.1% to 10% by weight, including exemplary values of 0.1%, 0.5%, 1%, 2%, 3%, 4%, 6%, 7%, 8%, 9%, 10%, or any subrange formed from the above exemplary values.
[0059] In some aspects, the at least one polymer can include a biodegradable polymer. In some aspects, the at least one polymer can include polyflactic acid) (PLA), polyfglycolic acid) (PGA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polybutylene succinate (PBS), polybutylene adipate terephthalate (PBAT), poly(3-hydroxybutyrate) (PHB), poly(hydroxyvalerate) (PHV), poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), poly(sebacic acid), a poly(orthoester), copolymers thereof, or combinations thereof. In some aspects, the at least one polymer can include PLA. In some aspects, the at least one polymer can include PGA. In some aspects, the at least one polymer can include PLGA. In some aspects, the at least one polymer can include PCL. In some aspects, the at least one polymer can include PBS. In some aspects, the at least one polymer can include PBAT. In some aspects, the at least one polymer can include PHB. In some aspects, the at least one polymer can include PHV. In some aspects, the at least one polymer can include PHBV. In some aspects, the at least one polymer can include poly(sebacic acid). In some aspects, the at least one polymer can include poly(orthoester). In some aspects, the at least one polymer can include a combination of two or more of the above polymers. Other suitable polymers can be readily identified.
[0060] In some aspects, the polymer mixture further includes at least one solvent. Representative examples of suitable solvents include, but are not limited to, acetone, methyl ethyl ketone, tetrahydrofuran, ethyl acetate, dimethylformamide, dimethyl sulfoxide, acetonitrile, methanol, ethanol, isopropanol, water, chloroform, dichloromethane, acetic acid, formic acid, or combinations thereof. In some aspects,Attorney Docket No. IO3362-137WO1
[0061] the at least one solvent can include a fluorinated solvent, such as trifluoroethanol or hexafluoroisopropanol.
[0062] In some aspects, the method can further include fabricating an article from the polymer mixture. Any suitable fabrication method for preparing polymeric articles from polymer mixtures can be used.
[0063] In some aspects, fabricating the article can include casting, such as solution casting or melt casting. Solution casting is a film-forming method where a polymer is dissolved in a suitable solvent, the resulting solution is spread onto a substrate or into a mold, and the solvent is evaporated to leave behind a solid polymer film or membrane. Melt casting is a process where a solid material is heated just above its melting point, turned into a low-viscosity liquid, and then poured into a mold or casing where it cools and solidifies into the desired shape.
[0064] In some aspects, fabricating the article can include molding, such as injection molding. Injection molding is a manufacturing process where molten material (most often plastic) is injected under pressure into a metal mold cavity, allowed to cool and solidify, and then ejected as a finished part.
[0065] In some aspects, fabricating the article can include extrusion, such as fiber spinning or profile extrusion. Fiber spinning is the process of converting a polymer in a fluid state (melt or solution) into continuous, solid filaments by extruding it through fine openings (a spinneret), followed by solidification and often drawing to orient chains and tailor properties. Profile extrusion is a continuous manufacturing process in which a material (typically molten plastic) is forced through a shaped die to produce long parts with a constant cross-section.
[0066] In some aspects, fabricating the article can include electrospinning. Electrospinning is a voltage-driven fabrication process that uses electrostatic forces to produce ultrathin polymer fibers, typically ranging from nanometers to micrometers in diameter. The technique relies on an electrohydrodynamic phenomenon where a polymer solution is drawn and stretched by an applied electric field to create nanofibers.
[0067] In some aspects, fabricating the article can include additive manufacturing. Additive manufacturing of polymers is the production of 3D parts directly from digital modelsAttorney Docket No. IO3362-137WO1
[0068] by depositing or solidifying polymer material in successive layers, rather than removing material from a bulk form.
[0069] In some aspects, fabricating the article can include sintering.
[0070] In some aspects, the method can further include drying the article. The article may be dried without the application of heat or with the application of heat, such as in an oven. In some aspects, drying the article can be performed for 12 hours to 48 hours, including exemplary values of 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, or any subrange formed from the above exemplary values.
[0071] In some aspects, the method can further include contacting the article with water to form the porous polymeric article. In some aspects, contacting the article with water can result in leaching of the salt or the sugar from the article. In some aspects, contacting the article with water can include immersing the article in the water. In some aspects, contacting the article with water can include washing the article with water. In some aspects, the water can include deionized water.
[0072] In some aspects, the method can further include drying the porous polymeric article. The porous polymeric article may be dried without the application of heat or with the application of heat, such as in an oven.
[0073] In some aspects, the porous polymeric article can be an implant or a portion or segment thereof. In some aspects, the implant can be a medical implant.
[0074] In some aspects, the porous polymeric article can be an ocular implant. In some aspects, the porous polymeric article can be an intravitreal implant, a subconjunctival implant, a subtenon implant, a retrobulbar implant, or a suprachoroidal implant.
[0075] In some aspects, the ocular implant can have a length from 0.1 cm to 5 cm, for example, from 0.5 cm to 3 cm, or from 1 cm to 3 cm. In some aspects, the ocular implant can have a length from 0.1 cm to 5 cm, from 0.5 cm to 5 cm, from 1 cm to 5 cm, from 2 cm to 5 cm, from 3 cm to 5 cm, from 4 cm to 5 cm, from 0.1 cm to 4 cm, from 0.5 to 4 cm, from 1 cm to 4 cm, from 2 cm to 4 cm, from 3 cm to 4 cm, from 0.1 cm to 3 cm, from 0.5 cm to 3 cm, from 1 cm to 3 cm, from 2 cm to 3 cm, from 0.1 cm to 2 cm, from 0.5 cm to 2 cm, from 1 cm to 2 cm, from 0.1 cm to 1 cm, from 0.5 to 1 cm, or from 0.1 to 0.5 cm.Attorney Docket No. IO3362-137WO1
[0076] In some aspects, the method can further include loading the porous polymeric article with a cargo. In some aspects, the cargo can include a therapeutic agent. The term “therapeutic agent” includes any synthetic or naturally occurring biologically active compound or composition of matter which, when administered to an organism (either human or a nonhuman animal), induces a desired pharmacologic, immunogenic, and / or physiologic effect by local and / or systemic action. The term therefore encompasses those compounds or chemicals traditionally regarded as drugs, vaccines, and biopharmaceuticals, including molecules such as proteins, peptides, hormones, nucleic acids, gene constructs, and the like. Examples of therapeutic agents are described in well-known literature references such as the Merk Index (14thEdition), the Physician’s Desk Reference (64thEdition), and The Pharmacological Basis of Therapeutics (12thEdition), and they include, without limitation, medicaments; vitamins; mineral supplements, substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment. For example, the term “therapeutic agent” includes compounds or compositions for use in all of the major therapeutic areas including, but not limited to, adjuvants; anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations, anorexics, anti-inflammatory agents, antiepileptics, local and general anesthetics, hypnotics, sedatives, antipsychotic agents, neuroleptic agents, antidepressants, anxiolytics, antagonists, neuron blocking agents, anticholinergic and cholinomimetic agents, antimuscarinic and muscarinic agents, antiandrenergics, antiarrhythmics, antihypertensive agents, hormones, and nutrients, antiarthritics, antiasthmatic agents, anticonvulsants, antihistamines, antinauseants, antineoplastics, antipruritics, antipyretics, antispasmodics, cardiovascular preparations (including calcium channel blockers, beta blockers, and beta-agonists), antihypertensives, diuretics, vasodilators, central nervous system stimulants, cough and cold preparations, decongestants, diagnostics, bone growth stimulants and bone resorption inhibitors, immunosuppressives, muscle relaxants, psychostimulants, sedatives, tranquilizers, proteins, peptides, and fragments thereof (whether naturally occurring, chemically synthesized or recombinantly produced), and nucleic acid molecules (polymeric forms of two or more nucleotides, either ribonucleotides (RNA) or deoxyribonucleotides (DNA) including both double andAttorney Docket No. IO3362-137WO1
[0077] single-stranded molecules, gene constructs, expression vectors, antisense molecules and the like), small molecules and other biologically active macromolecules such as, for examples, proteins and enzymes. The agent may be a biologically active agent used in medical, including veterinary, applications, and in agriculture, such as with plants, as well as other areas.
[0078] Representative examples of therapeutic agents that can be the cargo include, but are not limited to, bevacizumab, ranibizumab, aflibercept, brolucizumab, faricimab-svoa, pegcetacoplan, triamcinolone acetonide, dexamethasone, fluocinolone acetonide, vancomycin, ceftazidibe, amikacin, amphotericin B, voriconazole, foscarnet, moxifloxacin, cefuroxime, and the like.
[0079] In view of the described methods, certain more particular aspects of the disclosure are described below. These particularly recited aspects should not, however, be interpreted to have any limiting effect on any different claims containing different or more general teachings described herein, or that the “particular” aspects are somehow limited in some way other than the inherent meanings of the language and formulae literally used therein.
[0080] Aspect 1. A method of manufacturing a porous polymeric article having an average pore diameter from 125 to 375 nanometers, the method comprising: combining at least one polymer and at least one sugar to create a polymer mixture; fabricating an article from the polymer mixture;
[0081] drying the article; and
[0082] contacting the article with water to form the porous polymeric article.
[0083] Aspect 2. The method of any aspect herein, such as aspect 1, wherein the at least one sugar comprises sucrose, glucose, fructose, lactose, trehalose, maltose, xylose, allulose, or combinations thereof.
[0084] Aspect 3. The method of any aspect herein, such as aspect 1 or aspect 2, wherein the at least one sugar comprises sucrose.
[0085] Aspect 4. The method of any aspect herein, such as any one of aspects 1-3, wherein the at least one sugar is present in the polymer mixture at a concentration from 0.1% to 10% by weight.Attorney Docket No. IO3362-137WO1
[0086] Aspects. The method of any aspect herein, such as any one of aspects 1-4, wherein the average pore diameter is from 150 to 350, 175 to 325, 175 to 300, or 200 to 275 nanometers.
[0087] Aspect 6. A method of manufacturing a porous polymeric article having an average pore diameter from 400 to 1200 nanometers, the method comprising: combining at least one polymer and at least one salt to create a polymer mixture; fabricating the polymer mixture into an article;
[0088] drying the article; and
[0089] contacting the article with water to form the porous polymeric article.
[0090] Aspect 7. The method of any aspect herein, such as aspect 6, wherein the at least one salt comprises a sulfonate salt.
[0091] Aspect 8. The method of any aspect herein, such as aspect 6 or aspect 7, wherein the at least one salt comprises 4-(2-hydroxyethyl)-i-piperazineethanesulfonate (HEPES) salt, 3-(Ar-morpholino)propanesulfonate (MOPS) salt, piperazine-N,N'-bis(2-ethanesulfonate) (PIPES) salt, 2-{[i,3-Dihydroxy-2-(hydroxymethyl)propan-2-yl]amino}ethane-i-sulfonate (TES) salt, 3-[4-(2-Hydroxyethyl)piperazin-i-yl]propane-i-sulfonate (EPPS) salt, 3-[4-(2-Hydroxyethyl)piperazin-i-yl]propane-i-sulfonate (TAPS) salt, or combinations thereof.
[0092] Aspect 9. The method of any aspect herein, such as any one of aspects 6-8, wherein the at least one salt comprises a sodium salt, a potassium salt, or combinations thereof.
[0093] Aspect 10. The method of any aspect herein, such as any one of aspects 6-9, wherein the at least one salt is present in the polymer mixture at a concentration from 0.1% to 10% by weight.
[0094] Aspect 11. The method of any aspect herein, such as any one of aspects 1-10, wherein the at least one polymer comprises a biodegradable polymer.
[0095] Aspect 12. The method of any aspect herein, such as any one of aspects 1-11, wherein the at least one polymer comprises poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polybutylene succinate (PBS), polybutylene adipate terephthalate (PBAT), poly(3-hydroxybutyrate) (PHB), poly(hydroxyvalerate) (PHV), poly(3-hydroxybutyrate-co-Attorney Docket No. IO3362-137WO1
[0096] 3-hydroxyvalerate) (PHBV), polyfsebacic acid), a poly(orthoester), copolymers thereof, or combinations thereof.
[0097] Aspect 13. The method of any aspect herein, such as any one of aspects 1-12, wherein the at least one polymer comprises PCL.
[0098] Aspect 14. The method of any aspect herein, such as any one of aspects 1-13, wherein the polymer mixture further comprises at least one solvent.
[0099] Aspect 15. The method of any aspect herein, such as aspect 14, wherein the at least one solvent comprises a fluorinated solvent.
[0100] Aspect 16. The method of any aspect herein, such as aspect 14 or aspect 15, wherein the at least one solvent comprises hexafluoroisopropanol.
[0101] Aspect 17. The method of any aspect herein, such as any one of aspects 1-16, wherein fabricating the article comprises casting, such as solution casting or melt casting.
[0102] Aspect 18. The method of any aspect herein, such as any one of aspects 1-17, wherein fabricating the article comprises molding, such as injection molding.
[0103] Aspect 19. The method of any aspect herein, such as any one of aspects 1-18, wherein fabricating the article comprises extrusion, such as fiber spinning or profile extrusion.
[0104] Aspect 20. The method of any aspect herein, such as any one of aspects 1-19, wherein fabricating the article comprises electrospinning.
[0105] Aspect 21. The method of any aspect herein, such as any one of aspects 1-20, wherein fabricating the article comprises additive manufacturing.
[0106] Aspect 22. The method of any aspect herein, such as any one of aspects 1-21, wherein fabricating the article comprises sintering.
[0107] Aspect 23. The method of any aspect herein, such as any one of aspects 1-22, wherein drying the article occurs without application of heat.
[0108] Aspect 24. The method of any aspect herein, such as any one of aspects 1-22, wherein drying the article occurs with application of heat.
[0109] Aspect 25. The method of any aspect herein, such as any one of aspects 1-24, wherein drying the article occurs for a period of 12 hours to 48 hours.Attorney Docket No. IO3362-137WO1
[0110] Aspect 26. The method of any aspect herein, such as any one of aspects 1-25, wherein contacting the article with water results in leaching of the salt or the sugar from the article.
[0111] Aspect 27. The method of any aspect herein, such as any one of aspects 1-26, wherein contacting the article with water comprises immersing the article in the water.
[0112] Aspect 28. The method of any aspect herein, such as any one of aspects 1-27, wherein the water comprises deionized water.
[0113] Aspect 29. The method of any aspect herein, such as any one of aspects 1-28, further comprising drying the porous polymeric article.
[0114] Aspect 30. The method of any aspect herein, such as any one of aspects 1-29, wherein the porous polymeric article comprises an implant or a portion or segment thereof.
[0115] Aspect 31. The method of any aspect herein, such as any one of aspects 1-30, wherein the porous polymeric article comprises an ocular implant.
[0116] Aspect 32. The method of any aspect herein, such as any one of aspects 1-31, wherein the porous polymeric article comprises an intravitreal implant, a subconjunctival implant, a subtenon implant, a retrobulbar implant, or a suprachoroidal implant.
[0117] Aspect 33. The method of any aspect herein, such as any one of aspects 1-32, wherein the porous polymeric article comprises an intravitreal implant.
[0118] Aspect 34. The method of any aspect herein, such as any one of aspects 1-33, further comprising loading the porous polymeric article with a cargo.
[0119] Aspect 35. The method of any aspect herein, such as aspect 34, wherein the cargo comprises a therapeutic agent.
[0120] A number of aspects of the disclosure have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the disclosure. Accordingly, other aspects are within the scope of the following claims.
[0121] By way of non-limiting illustration, examples of certain aspects of the present disclosure are given below.Attorney Docket No. IO3362-137WO1
[0122] EXAMPLES
[0123] The following examples are set forth below to illustrate the methods claimed herein, along with associated methods and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations of the present disclosure, which are apparent to one skilled in the art.
[0124] Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric. Only reasonable, routine experimentation will be required to optimize these process conditions.
[0125] Electrospinning of Porous Nanofibrous PCL Mats
[0126] An automated electrospinning system was used as shown in FIG. 1. PCL was dissolved in acetic acid at 18% w / v. HEPES sodium salt or sucrose were added at 3% to the PCL solution. Solutions were electrospun to prepare nanofibrous mats at voltage of 15 kV, flow rate of 0.8 mL / h, and a needle-to-collector distance of 12 cm. Following electrospinning, fibers were sintered under vacuum to melt the outer layer and remove surface porosity. Sintered materials were washed in deionized water to remove the water soluble HEPES sodium salt or sucrose, leaving nanopores after washing. Scanning electronic microscopy (SEM) was used to characterize the morphology. SEM images of the PCL / salt and PCL / sucrose nanofibers after electrospinning may be found in FIGs. 2A and 2B. SEM images of the nanoporosity of PCL with different HEPES sodium salt concentrations can be found in FIG. 3. Cytotoxicity of the PCL / salt and PCL / sucrose mats to exposed ARPE-19 cells were measured by the direct contact methods and extract exposure method. Results are shown in FIG. 4.
[0127] PCL nanofibers were successfully produced with both salt and sugar based porogens. PCL prepared with these porogens demonstrated negligible cytotoxicity to ARPE-19 cells via direct contact and extract exposure methods. Electrospinning parameters and porogen concentrations can be modulated to enable long-term therapeutic release of small and large molecules.Attorney Docket No. IO3362-137WO1
[0128] Solution Casting of Porous PCL Films
[0129] Biodegradable PCL nanoporous ophthalmic implants were fabricated via solvent casting and porogen leaching to enable long term-controlled release. Briefly, 0.5 g of a combination of PCL and water-soluble porogens (HEPES sodium salt or sucrose) was dissolved in volatile solvent, and the solution was continuously stirred overnight. Five mass ratios of PCL to porogen (100:0, 98:2, 95:5, 93:7, 90:10) were studied to assess the impact of porous structure of the PCL film on drug release. The prepared solutions were poured into silicon molds and dried for 24 hours under a fume hood to form thin-film implants. After drying, the PCL / porogen implants were washed in deionized water to leach out the water-soluble porogens, resulting in the formation of nanoporous structures. A scheme outlining the procedure can be found in FIG. 8. SEM images were obtained of the nanopores before (FIG. 9A) and after (FIG. 9B) porogen leaching in the PCL implant produced with 5% HEPES salt concentration. SEM images were also obtained before (FIG. 10A) and after (FIG. 10B) porogen leaching in the PCL implant produced with 5% sucrose concentration. Table 1 below provides the associated measurements.
[0130] Table 1. Porosity and pore size of PCL implants with 5% HEPES sodium salt and sucrose
[0131] Sample Pore Pore Increase(nm) Porous Name Diameter(nm) Diameter(nm) Channel after 24-48hr
[0132] incubation
[0133] 5% 36.2±21.8 8OO±395 763±373 Yes HEPES
[0134] Salt
[0135] 5% Sugar 21.6±I6.5 252±112 23i±95-5 Yes
[0136]
[0137] These SEM results demonstrate that both groups formed porous channels but porogen selection influences the pore formation in PCL implants. 5% HEPES salt showed much greater pore enlargement after incubation than 5% sucrose. While notAttorney Docket No. IO3362-137WO1
[0138] wishing to be bound by any one theory, HEPES salt may tend to generate more irregular, interconnected networks, so after incubation, adjacent pores can open and merge, giving a larger apparent pore diameter. Sucrose may tend to form more discrete, geometry-defined pores, so the enlargement is smaller.
[0139] In vitro cytotoxicity was assessed by MTS assay conducted with ARPE-19 cells. For the direct contact method, 1 cm of different ratios of PCL / porogen implants were placed in the cell-seeded well plate for 24 hours. Results may be found in FIG. 12A. All the ratios of PCL / porogen implants showed negligible toxicity to the RPE cells during the 24-hour direct incubation.
[0140] For the extract exposure method, all PCL / porogen implants were immersed in 1 mL fresh media for 1 week. Implant-conditioned media was transferred to the cell-seeded well plate for 24 hours. Results maybe found in FIG. 12B. The extracts of all implants did not influence cell viability.
[0141] Tensile tests were performed using a Bose Electroforce mechanical tester. PCL implants were cut to 2 mm x 6 mm rectangular strips and pulled vertically with a uniaxial stretching until break of the strips at a speed of 1 mm / min. Results may be found in FIG. 11A and FIG. 11B. Pure PCL implants exhibited the highest tensile strength, demonstrating superior mechanical robustness compared with all samples. Porogen incorporation decreased tensile strength, with the greatest reduction observed at the higher porogen loading (95:5). The differences in strength are not extremely large, suggesting that the implants still retain measurable structural integrity even after modification with porogens.
[0142] In summary, SEM analysis confirmed that PCL implants formed pores capable of supporting controlled drug diffusion. The increase in pore diameter found indicates that porosity can be tailored to enable long-term release of both small and large therapeutics.
[0143] The references cited herein are hereby incorporated by reference to disclose and describe the methods or materials in connection with which the publications are cited or to provide background for the present disclosure. Any incorporation by reference of documents herein is limited such that no subject matter is incorporated by reference that is contrary to the explicit disclosure herein. In the event of inconsistentAttorney Docket No. IO3362-137WO1
[0144] usages between this document and those documents so incorporated by reference herein, the use in the incorporated references should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.
[0145] The methods of the appended claims are not limited in scope by the specific compositions and methods described herein, which are intended as illustrations of a few aspects of the claims, and any compositions and methods that are functionally equivalent are intended to fall within the scope of the claims. Various modifications of the compositions and methods, in addition to those shown and described herein, are intended to fall within the scope of the appended claims. Further, while only certain representative compositions and method steps disclosed herein are specifically described, other combinations of the compositions and method steps also are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents maybe explicitly mentioned herein; however, other combinations of steps, elements, components, and constituents are included, even though not explicitly stated.
Claims
Attorney Docket No. IO3362-137WO1WHAT IS CLAIMED IS:
1. A method of manufacturing a porous polymeric article having an average pore diameter from 125 to 375 nanometers, the method comprising:combining at least one polymer and at least one sugar to create a polymer mixture; fabricating an article from the polymer mixture;drying the article; andcontacting the article with water to form the porous polymeric article.
2. The method of claim 1, wherein the at least one sugar comprises sucrose, glucose, fructose, lactose, trehalose, maltose, xylose, allulose, or combinations thereof.
3. The method of claim 1 or claim 2, wherein the at least one sugar comprises sucrose.
4. The method of any one of claims 1-3, wherein the at least one sugar is present in the polymer mixture at a concentration from 0.1% to 10% by weight.
5. The method of any one of claims 1-4, wherein the average pore diameter is from 150 to 350, 175 to 325, 175 to 300, or 200 to 275 nanometers.
6. A method of manufacturing a porous polymeric article having an average pore diameter from 400 to 1200 nanometers, the method comprising:combining at least one polymer and at least one salt to create a polymer mixture; fabricating the polymer mixture into an article;drying the article; andcontacting the article with water to form the porous polymeric article.Attorney Docket No. IO3362-137WO17. The method of claim 6, wherein the at least one salt comprises a sulfonate salt.
8. The method of claim 6 or claim 7, wherein the at least one salt comprises 4-(2-hydroxyethyl)-i-piperazineethanesulfonate (HEPES) salt, 3-( -morpholino)propanesulfonate (MOPS) salt, piperazine-N,N'-bis(2-ethanesulfonate) (PIPES) salt, 2-{[i,3-Dihydroxy-2-(hydroxymethyl)propan-2-yl]amino}ethane-i-sulfonate (TES) salt, 3-[4-(2-Hydroxyethyl)piperazin-i-yl]propane-i-sulfonate (EPPS) salt, 3-[4-(2-Hydroxyethyl)piperazin-i-yl]propane-i-sulfonate (TAPS) salt, or combinations thereof.
9. The method of any one of claims 6-8, wherein the at least one salt comprises a sodium salt, a potassium salt, or combinations thereof.
10. The method of any one of claims 6-9, wherein the at least one salt is present in the polymer mixture at a concentration from 0.1% to 10% by weight.
11. The method of any one of claims 1-10, wherein the at least one polymer comprises a biodegradable polymer.
12. The method of any one of claims 1-11, wherein the at least one polymer comprises poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactide-co-glycolide) (PLGA), polycaprolactone (PCL), polybutylene succinate (PBS), polybutylene adipate terephthalate (PBAT), poly(3-hydroxybutyrate) (PHB), poly(hydroxyvalerate) (PHV), poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), poly(sebacic acid), a poly(orthoester), copolymers thereof, or combinations thereof.
13. The method of any one of claims 1-12, wherein the at least one polymer comprises PCL.Attorney Docket No. IO3362-137WO114- The method of any one of claims 1-13, wherein the polymer mixture further comprises at least one solvent.
15. The method of claim 14, wherein the at least one solvent comprises a fluorinated solvent.
16. The method of claim 14 or claim 15, wherein the at least one solvent comprises hexafluoroisopropanol.
17. The method of any one of claims 1-16, wherein fabricating the article comprises casting, such as solution casting or melt casting.
18. The method of any one of claims 1-17, wherein fabricating the article comprises molding, such as injection molding.
19. The method of any one of claims 1-18, wherein fabricating the article comprises extrusion, such as fiber spinning or profile extrusion.
20. The method of any one of claims 1-19, wherein fabricating the article comprises electrospinning.
21. The method of any one of claims 1-20, wherein fabricating the article comprises additive manufacturing.
22. The method of any one of claims 1-21, wherein fabricating the article comprises sintering.Attorney Docket No. IO3362-137WO123. The method of any one of claims 1-22, wherein drying the article occurs without application of heat.
24. The method of any one of claims 1-22, wherein drying the article occurs with application of heat.
25. The method of any one of claims 1-24, wherein drying the article occurs for a period of 12 hours to 48 hours.
26. The method of any one of claims 1-25, wherein contacting the article with water results in leaching of the salt or the sugar from the article.
27. The method of any one of claims 1-26, wherein contacting the article with water comprises immersing the article in the water.
28. The method of any one of claims 1-27, wherein the water comprises deionized water.
29. The method of any one of claims 1-28, further comprising drying the porous polymeric article.
30. The method of any one of claims 1-29, wherein the porous polymeric article comprises an implant or a portion or segment thereof.
31. The method of any one of claims 1-30, wherein the porous polymeric article comprises an ocular implant.Attorney Docket No. IO3362-137WO132. The method of any one of claims 1-31, wherein the porous polymeric article comprises an intravitreal implant, a subconjunctival implant, a subtenon implant, a retrobulbar implant, or a suprachoroidal implant.
33. The method of any one of claims 1-32, wherein the porous polymeric article comprises an intravitreal implant.
34. The method of any one of claims 1-33, further comprising loading the porous polymeric article with a cargo.
35. The method of claim 34, wherein the cargo comprises a therapeutic agent.
